Extract
Langerhans cell histiocytosis (LCH) is currently considered a rare neoplastic disease with an inflammatory component, driven by genomic alterations in the mitogen-activating protein kinase (MAPK) pathway, including BRAFV600E, MAP2K1 mutations and BRAF deletions [1, 2]. Lung involvement is frequently observed in adult LCH patients, almost exclusively in young smokers of both sexes [3]. The aetiology of LCH, including pulmonary LCH (PLCH), remains unknown. A viral triggering factor of LCH has long been suspected, but the results of studies are inconclusive [4, 5].
Abstract
Compared to control lung tissues from smokers, MCPyV DNA is rarely detected in PLCH lesions and is not associated with alterations of the MAPK pathway. A viral trigger in PLCH pathogenesis remains elusive. https://bit.ly/2xKmkIo
Acknowledgements
The authors thank S. Mercier-Delarue for performing plasmid experiments (Infectious Agents Dept, Virology Unit, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France) and M. Mao (Pulmonology Dept, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France) for her technical assistance.
Footnotes
Conflict of interest: F. Jouenne has nothing to disclose.
Conflict of interest: J. Le Goff has nothing to disclose.
Conflict of interest: E. Bugnet has nothing to disclose.
Conflict of interest: M. Salmona has nothing to disclose.
Conflict of interest: V. Meignin has nothing to disclose.
Conflict of interest: G. Lorillon reports support for travel and accommodation from Vitalaire and Chiesi outside the submitted work.
Conflict of interest: A. Sadoux has nothing to disclose.
Conflict of interest: J. Cherot has nothing to disclose.
Conflict of interest: C. Lebbé reports honoraria from, and consultancy, and serving on a speakers bureau and an advisory board for Amgen; grants and honoraria from, and consultancy, and serving on a speakers bureau and an advisory board for BMS; grants and honoraria from, and consultancy, and service in an advisory role and on an advisory board for, and travel and accomodation for meetings from MSD; grants and honoraria, and consultancy, and service in a speakers bureau, in an advisory role and on an advisory board for Roche and Novartis; consultancy for and honoraria from Pierre Fabre; consultancy for Sanofi and Merck Serono; and honoraria from Pfizer and Incyte, all outside the submitted work.
Conflict of interest: S. Mourah reports consulting for Novartis and Roche outside the submitted work.
Conflict of interest: A. Tazi reports personal fees from Bristol-Myers Squibb for speaking at a conference, and travel and accommodation support from Boehringer Ingelheim, Teva, Vitalaire and AstraZeneca, all outside the submitted work.
- Received September 4, 2019.
- Accepted March 24, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.